Precision BioSciences, Inc.(NASDAQ : DTIL)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||0.26%||7.68||0.7%||$536.86m|
|GILD||Gilead Sciences, Inc.||-0.55%||68.53||1.0%||$504.56m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.11%||516.62||2.7%||$432.65m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.09%||173.49||2.0%||$412.31m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.28%||217.09||1.9%||$311.54m|
|CRSP||CRISPR Therapeutics AG||5.58%||106.64||0.6%||$171.41m|
|BNGO||Bionano Genomics, Inc.||22.45%||5.40||0.0%||$162.77m|
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.